The plasma ChAT levels between the AD patients who were on ChEIs therapy,compared to those who were not, partially supported the above notion, since the varianceof ChAT was different in those taking rivastigmine, which indicates a bidirectionalinfluence of this drug on ChAT protein expression in the plasma. The gene discussed is CHAT; the disease is Alzheimer disease.